Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline

Oppenheimer initiated coverage of Ocugen (NASDAQ:OCGN) with an Outperform rating and a $10 price target on Wednesday, positioning the clinical-stage gene therapy company as an emerging leader in blinding ocular disorders.